A Phase II Study of Single-Agent OSI-7904L in Patients With Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Have Failed First-Line Therapy

NCT00116909 Phase 2 COMPLETED

Multi-center, Phase II study to evaluate the efficacy and safety of OSI-7904Lin head and neck cancer in patients who have failed first-line therapy

Details

Lead sponsor	OSI Pharmaceuticals
Phase	Phase 2
Status	COMPLETED
Enrolment	85
Start date	2004-08
Completion	2005-08

Conditions

• Locally Recurrent or Metastatic Cancer of the Head and Neck
• Must Have Failed First-Line Therapy

Interventions

• OSI 7904L

Countries

United States